Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,089–1,096 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
BridgeBio Pharma Inc. TRUSELTIQ (infigratinib)- (PROOF 302) Urothelial Carcinoma Phase 3 Ongoing Oral Oncology
BridgeBio Pharma Inc. Infigratinib - (ACCEL) Hypochondroplasia Phase 2 Ongoing Oral Genetic Disorder
BridgeBio Pharma Inc. Encaleret - (RECLAIM-HP) Chronic hypoparathyroidism Phase 3 Trial Planned oral Endocrinology
BridgeBio Pharma Inc. PTR-01 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Ongoing Intravenous Genetic Disorder
BridgeBio Pharma Inc. TRUSELTIQ (infigratinib) Recurrent Glioblastoma Phase 2 Ongoing Oral Oncology
Bright Minds Biosciences Inc. BMB-101 - (BREAKTHROUGH) Absence Epilepsy & Dravet Syndrome Phase 2 Data Released Oral Neurology
Bright Minds Biosciences Inc. BMB-101 - (BREAKTHROUGH) Absence Epilepsy & Dravet Syndrome Phase 2 Data Released Oral Neurology
Bristol-Myers Squibb Company Neoadjuvant nivolumab (N) + chemotherapy - (CheckMate-816) Non-small cell lung cancer (NSCLC) Phase 3 Data Released Intravenous Oncology